Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
BEVERLY, Mass. and TORONTO, Ontario , Aug. 09, 2017 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced the launch of its TrakJector™ micromanipulator system which offers a unique, intuitive control system for fast and accurate ICSI and embryo biopsy procedures in the ART laboratory.
David Wolf, President and Chief Executive Officer stated, “The TrakJector micromanipulator system complements Hamilton Thorne’s existing product line of precision laser instruments and image analysis systems that are used today in hundreds of In Vitro Fertilization clinics worldwide. The introduction of the TrakJector represents a meaningful milestone for us as we move towards our goal of providing a full range of high performance, best-in-class solutions for the ART market.”
TrakJector features include:
- True one-handed operation using the AIOtrackball (All-in-One Trackball) in conjunction with the MIUmotOil (Motorized Oil Injection Unit).
- Easy to control both the injection holding pressure and the motorized movement using the trackball and the two buttons.
- The integrated, ergonomic GELpillow allows hands to stay relaxed during extended operating sessions.
- An adjustable velocity setting permits balancing between operators and different magnifications.
- Coarse adjustments are offered in all relevant directions.
- The ability to disengage movement in the y-axis coupled with the superb accuracy allows an injection movement of proper parallelism.
- The TrakJector microinjection holder provides a two-step adjustment for the injection and holding angles. Both coarse and fine adjustments are easily made using a rotating control.
- The swing out mechanism permits easy access to the micropipettes. Combine this with the automatic HOME function for a fast and reliable way to exchange micropipettes and return them back to the original working position.
Designed and manufactured in Germany, the TrakJector micromanipulators offer outstanding performance in smooth/fine control, precision (tolerance less than 1 µm), speed, mechanical stability, low-maintenance operation, and easy cleaning. TrakJector is available in both motorized and manual oil injector versions. In the future, a manual air injection unit will be available. The TrakJector fits on all common inverted microscopes from Leica, Olympus, Nikon and ZEISS.
The TrakJector system is available for sale through Hamilton Thorne’s growing direct sales presence in the Americas and Europe and through its worldwide distribution network.
About Hamilton Thorne Ltd. (https://www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com
For more information, please contact: David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 [email protected] Michael Bruns, CFO Hamilton Thorne Ltd. 978-921-2050 [email protected]
